Connect with us

Healthcare

What A Medical Cure For Being ‘Too High’ Could Look Like

Published

on

A pill to cure the symptoms of a cannabis overdose would be a blessing, saving emergency medical professionals a lot of time and energy.

Maybe you ate too many pot brownies, or perhaps you thought you could smoke the whole blunt on your own. Regardless of how you did it, at one time or another most cannabis users have found themselves way too high for their own good. 

While a marijuana “overdose,” medically called Acute Cannabinoid Overdose (ACO), is rarely linked to fatality, it can still be an altogether terrible and even terrifying experience. Sometimes the negative side effects of ACO are so bad that people end up in the emergency room. While medical professionals can monitor these patients and try to treat specific symptoms, there is no cure-all for being too high. At least there wasn’t, until now. 

drug is in the works from the pharmaceutical company Anebulo that aims to treat cannabinoid intoxication, and quickly. “ANEB-001 is being developed with the intent to quickly and effectively reverse the negative effects of cannabinoid intoxication within one hour of administration,” according to the Anebulo Pharmaceuticals website. This drug aims to target the human CB1 receptors, thus blocking THC’s ability to have its intense and negative effects on those who have over-consumed.

The drug is still in the testing phase, but is showing promise, as it has now entered phase two of clinical trials. If the drug is successful and works as quickly as it aims to, it may greatly assist emergency medical personnel when dealing with patients who have mistakenly gotten too high. The timing for this drug may also be very fortunate. Marijuana is, after all, more prevalent than ever before in mainstream American society. 

It is, however, important to note that just because marijuana is becoming legal in more places it does not mean more people are experiencing ACO as a result of this legalization. According to a 2021 study that tracked hospitalizations within states that recently legalized marijuana, “Legalization was not associated with a change in the rate of cannabis-related ED visits in our study. More research is needed regarding changing methods of cannabis ingestion and trends among specific age groups.”  

There is one trend, interestingly, that has healthcare professionals and others nervous about cannabis toxicity, and it isn’t legalization. According to a recent study on cannabinoid toxicity published by StatPearls, “Despite the wider availability of cannabis, most significant cannabinoid toxicity is likely due to the abuse of synthetic cannabinoids, which are known to have more adverse effects.” It is synthetic marijuana, and to a lesser extent, the wide availability of strong THC edibles (getting into the wrong or unaware mouths) that has the potential to really spike cannabis-related trips to the emergency room.

cannabis bud

Photo by eskymaks/Getty Images

This drug to cure cannabinoid overdose could come in very handy to emergency medical workers faced with these new more potent methods of consuming marijuana. After all, while ACO is not likely to cause death, it can require significant and immediate medical attention. And even with this medical attention, the current remedies are limited. According to Opiant Pharmaceuticals, “There are no FDA approved medicines to treat Acute Cannabinoid Overdose. Current treatment is largely supportive and symptom-driven, requiring emergency medical attention and in some instances, hospitalization.”

This is certainly not an ideal scenario for patients or doctors. This means a pill to cure the symptoms of a cannabis overdose would be a blessing, saving emergency medical professionals a lot of time and energy.

Source: https://thefreshtoast.com/cannabis/what-a-medical-cure-for-being-too-high-could-look-like/

Education News

AIIMS Gorakhpur Reservation Controversy: FIR Alleges Fake OBC Certificate Used Despite ₹80 Lakh Income

Published

on

By

A major controversy has emerged at AIIMS Gorakhpur after allegations surfaced that reservation benefits were misused to secure a postgraduate medical seat. A criminal case has been registered against former AIIMS Gorakhpur Executive Director Dr. G.K. Pal and his son, Dr. Oro Prakash Pal, over the alleged use of a forged Other Backward Class (OBC) Non-Creamy Layer certificate for admission to an MD course.

The case has triggered widespread debate within medical and administrative circles, raising serious questions about transparency and oversight in admissions to premier medical institutions.

FIR Filed on Court’s Direction

The First Information Report (FIR) was registered at the AIIMS police station following directions from Chief Judicial Magistrate Tvishi Srivastava. According to the complaint, the alleged offence took place on August 30, 2024, when forged documents were purportedly used to obtain an MD seat under the OBC reservation quota.

Sources indicate that the matter was subsequently brought to the attention of the Union Ministry of Health, prompting internal reviews and administrative action.

Alleged Income Far Above Eligibility Threshold

Central to the allegations is the claim that Dr. G.K. Pal and his wife Parvati Pal have a combined annual income exceeding ₹80 lakh. Under existing reservation rules, families with such income levels are not eligible for OBC Non-Creamy Layer benefits.

Following the emergence of the controversy, Dr. Pal was first removed from his position at AIIMS Gorakhpur and later relieved of responsibilities at AIIMS Patna. He is currently posted at JIPMER Puducherry. With the registration of the FIR, officials suggest that further legal and departmental action may follow, depending on the outcome of the investigation.

Complaint Highlights Systemic Concerns

The complaint was filed by Ashutosh Kumar Mishra, a resident of Divyanagar in the Cantonment area. He alleged that the events related to the case occurred between January and September 2024. The complainant argued that misuse of reservation provisions by individuals in senior positions undermines the integrity of public institutions and erodes trust in the medical education system.

The case has reignited concerns over whether verification mechanisms for reservation certificates are robust enough, particularly in high-stakes admissions.

Impact on Medical Community

The allegations have sent shockwaves through the medical fraternity. Experts believe that if the claims are substantiated, the case could prompt a broader review of admission procedures and lead to stricter scrutiny of category certificates across institutions like AIIMS.

Authorities have stated that all relevant documents will be carefully examined before taking further steps. The outcome of the investigation is expected to have far-reaching implications for accountability and compliance in medical admissions.

Questions Await Answers

As the probe continues, several key issues remain unresolved: whether reservation norms were deliberately violated, how verification processes failed, and whether similar cases may surface in the future. For now, the focus remains on the investigation and its potential consequences.

Continue Reading

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News